Company Profile

Adhera Therapeutics Inc (AKA: Marina Biotech Inc~Nastech Pharmaceutical Company Inc~MDRNA Inc~Cequent Pharmaceuticals)
Profile last edited on: 12/14/2023      CAGE: 3R7B3      UEI: GUZUKUU2UHH7

Business Identifier: Patient centric care for hypertension and pain
Year Founded
1983
First Award
2006
Latest Award
2006
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

4721 Emperor Boulevard Suite 350
Durham, NC 27702
   (919) 578-5901
   info@adherathera.com
   www.adherathera.com
Location: Multiple
Congr. District: 01
County: Durham

Public Profile

Previously dba Marina Biotech, Inc. (OTCQB: MRNA), a commercial stage pharmaceutical company focused on the development and commercialization of innovative therapeutics for hypertension, arthritis and pain, in October 2018, management announced a name change to Adhera Therapeutics, Inc. with the new ticker designation ATRX. The new name rbetter describes the company’s mission to develop and commercialize unique pharmaceutical therapies and leverage technology to improve patient outcomes. The firm had been organized around treating the intersection of arthritis, pain, hypertension, and oncology diseases using combination therapies of already approved drugs. Their first FDA approved drug, Prestalia®, contains perindopril arginine, an ACE inhibitor, and amlodipine, a dihydropyridine calcium channel blocker, and is indicated for the treatment of hypertension to lower blood pressure. The company is developing and commercializing late stage, non-addictive pain therapeutics. The company's 'next-generation of celecoxib,' including IT-102 and IT-103, are designed to control the dangerous side-effect of edema that prohibits the drug from being prescribed at higher doses. These have the potential of replacing opioids and combatting the opioid epidemic. Additionally we are developing therapeutic microbiome using the only orally bioavailable siRNAs platform against FAP and IBD.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
50-74
Revenue Range
5M-7.5M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
OTC : ATRX
IP Holdings
75-99

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2008 2 NIH $1,096,332
Project Title: Development of siRNAs to Prevent and Treat Influenza Infection

Key People / Management

  Robert C Moscato Jr -- CEO

  June Ameen -- Senior Vice President, Strategic Alliances

  J Michael French -- Former President

  Qing Ge

  James Anthony Mcswiggen

  Michael V Templin -- Former Chief Technology Officer